Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration

BMC Endocrine Disorders

Volumn 10, Issue , 2010, Pages

  Tong, Ming ^a,c   Longato, Lisa ^a,b   de la Monte, Suzanne M ^a,b,c  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; CERAMIDE; CHOLINE ACETYLTRANSFERASE; DIETHYLNITROSAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; SOMATOMEDIN; SOMATOMEDIN B RECEPTOR; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVITY; GENE EXPRESSION; INSULIN DEFICIENCY; INSULIN RESISTANCE; LIPID DIET; MALE; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RAT; UPREGULATION;

EID: 77953004836     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-10-4     Document Type: Article

References (117)

1. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007, 65(12 Pt 2):S152-156. 10.1111/j.1753-4887.2007.tb00354.x, 18240540.
2. Launer LJ. Next steps in Alzheimer's disease research: interaction between epidemiology and basic science. Curr Alzheimer Res 2007, 4(2):141-143. 10.2174/156720507780362155, 17430237.
3. Wang XP, Ding HL. Alzheimer's disease: epidemiology, genetics, and beyond. Neurosci Bull 2008, 24(2):105-109. 10.1007/s12264-008-0105-7, 18369390.
4. de la Monte SM, Neusner A, Chu J, Lawton M. Epidemilogical Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis. J Alzheimers Dis 2009, 17(3):519-529.
5. Swann PF, Magee PN. Nitrosamine-induced carcinogenesis. The alklylation of nucleic acids of the rat by N-methyl-N-nitrosourea, dimethylnitrosamine, dimethyl sulphate and methyl methanesulphonate. Biochem J 1968, 110(1):39-47. 1187106, 5722690.
6. Espey MG, Miranda KM, Thomas DD, Xavier S, Citrin D, Vitek MP, Wink DA. A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Ann N Y Acad Sci 2002, 962:195-206. 10.1111/j.1749-6632.2002.tb04068.x, 12076975.
7. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab 2006, 32(5 Pt 1):403-414. 10.1016/S1262-3636(07)70298-7, 17110895.
8. Nicolls MR. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 2004, 1(1):47-54. 10.2174/1567205043480555, 15975085.
9. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007, 128(5):837-847. 10.1309/RTPM1PY6YGBL2G2R, 17951208.
10. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 2007, 11(1):105-117. ix, 10.1016/j.cld.2007.02.013, 17544974.
11. Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children. Clin Nutr 2007, 26(4):409-415. 10.1016/j.clnu.2007.02.002, 17449148.
12. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007, 22(Suppl 1):S20-27. 10.1111/j.1440-1746.2006.04640.x, 17567459.
13. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008, 14(2):193-199. 10.3748/wjg.14.193, 2675113, 18186554.
14. Bolzan AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res 2002, 512(2-3):121-134. 10.1016/S1383-5742(02)00044-3, 12464347.
15. Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF. Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci USA 1977, 74(6):2485-2489. 10.1073/pnas.74.6.2485, 432197, 142253.
16. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001, 50(6):537-546.
17. Doi K. [Studies on the mechanism of the diabetogenic activity of streptozotocin and on the ability of compounds to block the diabetogenic activity of streptozotocin (author's transl)]. Nippon Naibunpi Gakkai Zasshi 1975, 51(3):129-147.
18. Iwai S, Murai T, Makino S, Min W, Morimura K, Mori S, Hagihara A, Seki S, Fukushima S. High sensitivity of fatty liver Shionogi (FLS) mice to diethylnitrosamine hepatocarcinogenesis: comparison to C3H and C57 mice. Cancer Lett 2007, 246(1-2):115-121. 10.1016/j.canlet.2006.02.008, 16569478.
19. de la Monte SM, Tong M, Lester-Coll N, Plater M, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 2006, 10(1):89-109.
20. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 2004, 541:135-152.
21. Hoyer S, Lannert H, Noldner M, Chatterjee SS. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 1999, 106(11-12):1171-1188. 10.1007/s007020050232, 10651112.
22. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006, 9(1):13-33.
23. Murata M, Takahashi A, Saito I, Kawanishi S. Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol 1999, 57(8):881-887. 10.1016/S0006-2952(98)00370-0, 10086321.
24. Nukatsuka M, Sakurai H, Yoshimura Y, Nishida M, Kawada J. Enhancement by streptozotocin of O2- radical generation by the xanthine oxidase system of pancreatic beta-cells. FEBS Lett 1988, 239(2):295-298. 10.1016/0014-5793(88)80938-4, 2846360.
25. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000, 17(3):171-180. 10.1046/j.1464-5491.2000.00259.x, 10784220.
26. Robbiano L, Mereto E, Corbu C, Brambilla G. DNA damage induced by seven N-nitroso compounds in primary cultures of human and rat kidney cells. Mutat Res 1996, 368(1):41-47. 10.1016/S0165-1218(96)90038-5, 8637509.
27. Verdelho A, Madureira S, Ferro JM, Basile AM, Chabriat H, Erkinjuntti T, Fazekas F, Hennerici M, O'Brien J, Pantoni L, Salvadori E, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A, Inzitari D. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 2007, 78(12):1325-1330. 10.1136/jnnp.2006.110361, 17470472.
28. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006, 11(8):721-736. 10.1038/sj.mp.4001854, 16786033.
29. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005, 8(3):247-268.
30. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?. J Alzheimers Dis 2005, 7(1):63-80.
31. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007, 4(2):147-152. 10.2174/156720507780362137, 17430239.
32. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006, 20(4):298-301. 10.1097/01.wad.0000213866.86934.7e, 17132977.
33. Winocur G, Greenwood CE. Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol Aging 2005, 26(Suppl 1):46-49. 10.1016/j.neurobiolaging.2005.09.003, 16219391.
34. Winocur G, Greenwood CE, Piroli GG, Grillo CA, Reznikov LR, Reagan LP, McEwen BS. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav Neurosci 2005, 119(5):1389-1395. 10.1037/0735-7044.119.5.1389, 16300445.
35. Weinstock M, Shoham S. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Neural Transm 2004, 111(3):347-366. 10.1007/s00702-003-0058-y, 14991459.
36. Nitta A, Murai R, Suzuki N, Ito H, Nomoto H, Katoh G, Furukawa Y, Furukawa S. Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol Teratol 2002, 24(5):695-701. 10.1016/S0892-0362(02)00220-9, 12200200.
37. Biju MP, Paulose CS. Brain glutamate dehydrogenase changes in streptozotocin diabetic rats as a function of age. Biochem Mol Biol Int 1998, 44(1):1-7.
38. Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2006, 2(3):159-166. 10.1038/ncpneuro0124, 16932542.
39. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, Degroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates {beta}-amyloid in early AD. Neurology 2008, 70(6):440-448. 10.1212/01.WNL.0000265401.62434.36, 17942819.
40. Landreth G. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res 2007, 4(2):159-164. 10.2174/156720507780362092, 17430241.
41. Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Frolich L, Craft S. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging 2006, 27(1):38-41. 10.1016/j.neurobiolaging.2004.11.011, 16298239.
42. Reger MA, Craft S. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today (Barc) 2006, 42(11):729-739. 10.1358/dot.2006.42.11.1007675, 17171192.
43. Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006, 27(3):451-458. 10.1016/j.neurobiolaging.2005.03.016, 15964100.
44. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006, 199(2):265-273. 10.1016/j.expneurol.2006.01.018, 16515786.
45. Lyn-Cook LE, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM. Hepatic Ceramide May Mediate Brain Insulin Resistance and Neurodegeneration in Type 2 Diabetes and Non-alcoholic Steatohepatitis. J Alzheimers Dis 2009, 16(4):715-729.
46. Moroz N, Tong M, Longato L, Xu H, de la Monte SM. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 2008, 15(1):29-44.
47. Gilman S, Quinn NP. The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and other forms of idiopathic late-onset cerebellar atrophy. Neurology 1996, 46(5):1197-1199.
48. Gilman S, Sima AA, Junck L, Kluin KJ, Koeppe RA, Lohman ME, Little R. Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions. Ann Neurol 1996, 39(2):241-255. 10.1002/ana.410390214, 8967756.
49. Burk K, Globas C, Wahl T, Buhring U, Dietz K, Zuhlke C, Luft A, Schulz JB, Voigt K, Dichgans J. MRI-based volumetric differentiation of sporadic cerebellar ataxia. Brain 2004, 127(Pt 1):175-181. 10.1093/brain/awh013, 14570820.
50. Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 1999, 9(4):721-732.
51. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 2005, 20(Suppl 12):S29-36. 10.1002/mds.20537, 16092088.
52. Paviour DC, Price SL, Stevens JM, Lees AJ, Fox NC. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005, 64(4):675-679.
53. Berciano J. Olivopontocerebellar atrophy. A review of 117 cases. J Neurol Sci 1982, 53(2):253-272. 10.1016/0022-510X(82)90011-9, 7057212.
54. Mizutani T. [Neuropathological background of spinocerebellar degeneration--with special reference to autonomic nervous system lesions in olivopontocerebellar atrophy, Shy-Drager syndrome and multiple system atrophy]. No To Shinkei 1985, 37(7):675-685.
55. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Bargallo N, Juanes S, Tolosa E. Differential progression of brain atrophy in Parkinson disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 2009,
56. Averback P, Crocker P. Regular involvement of Clarke's nucleus in sporadic amyotrophic lateral sclerosis. Arch Neurol 1982, 39(3):155-156.
57. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, Mori E. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 1997, 38(6):925-928.
58. Larner AJ. The cerebellum in Alzheimer's disease. Dement Geriatr Cogn Disord 1997, 8(4):203-209. 10.1159/000106632, 9213064.
59. Wegiel J, Wisniewski HM, Dziewiatkowski J, Badmajew E, Tarnawski M, Reisberg B, Mlodzik B, De Leon MJ, Miller DC. Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations. Brain Res 1999, 818(1):41-50. 10.1016/S0006-8993(98)01279-7, 9914436.
60. Mori F, Piao YS, Hayashi S, Fujiwara H, Hasegawa M, Yoshimoto M, Iwatsubo T, Takahashi H, Wakabayashi K. Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. J Neuropathol Exp Neurol 2003, 62(8):812-819.
61. Tu PH, Robinson KA, de Snoo F, Eyer J, Peterson A, Lee VM, Trojanowski JQ. Selective degeneration fo Purkinje cells with Lewy body-like inclusions in aged NFHLACZ transgenic mice. J Neurosci 1997, 17(3):1064-1074.
62. Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, Duyckaerts C, Stankoff B, Pillon B, Skullerud K, Cruz-Sanchez FF, Bigio EH, Mackenzie IR, Gearing M, Juncos JL, Glass JD, Yokoo H, Nakazato Y, Mosaheb S, Thorpe JR, Uryu K, Lee VM, Trojanowski JQ. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 2004, 63(8):1376-1384.
63. Bigio EH, Vono MB, Satumtira S, Adamson J, Sontag E, Hynan LS, White CL, Baker M, Hutton M. Cortical synapse loss in progressive supranuclear palsy. J Neuropathol Exp Neurol 2001, 60(5):403-410.
64. Rusina R, Bourdain F, Matej R. [Multiple system atrophy and Alzheimer's disease: a case report of a rare association of two neuro-degenerative disorders]. Rev Neurol (Paris) 2007, 163(12):1239-1241.
65. Engel PA, Grunnet M. Atypical dementia and spastic paraplegia in a patient with primary lateral sclerosis and numerous necortical beta amyloid plaques: new disorder or Alzheimer's disease variant?. J Geriatr Psychiatry Neurol 2000, 13(2):60-64. 10.1177/089198870001300203, 10912726.
66. Sheridan PL, Hausdorff JM. The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer's disease. Dement Geriatr Cogn Disord 2007, 24(2):125-137. 10.1159/000105126, 17622760.
67. Thomann PA, Schlafer C, Seidl U, Santos VD, Essig M, Schroder J. The cerebellum in mild cognitive impairment and Alzheimer's disease - a structural MRI study. J Psychiatr Res 2008, 42(14):1198-1202. 10.1016/j.jpsychires.2007.12.002, 18215400.
68. Bertoni-Freddari C, Fattoretti P, Casoli T, Caselli U, Meier-Ruge W. Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Anal Quant Cytol Histol 1996, 18(3):209-213.
69. Fukutani Y, Cairns NJ, Rossor MN, Lantos PL. Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val-->Ile) mutation cases: a morphometric investigation. J Neurol Sci 1997, 149(2):177-184. 10.1016/S0022-510X(97)05399-9, 9171327.
70. Dickson DW, Wertkin A, Mattiace LA, Fier E, Kress Y, Davies P, Yen SH. Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol 1990, 79(5):486-493. 10.1007/BF00296107, 2158201.
71. Baloyannis SJ. Dendritic pathology in Alzheimer's disease. J Neurol Sci 2009, 283(1-2):153-157. 10.1016/j.jns.2009.02.370, 19296966.
72. Baloyannis SJ, Manolidis SL, Manolidis LS. Synaptic alterations in the vestibulocerebellar system in Alzheimer's disease--a Golgi and electron microscope study. Acta Otolaryngol 2000, 120(2):247-250. 10.1080/000164800750001026, 11603783.
73. Baloyannis SJ. Pathological alterations of the climbing fibres of the cerebellum in vascular dementia: a Golgi and electron microscope study. J Neurol Sci 2007, 257(1-2):56-61. 10.1016/j.jns.2007.03.003, 17448497.
74. Carson MJ, Slager UT, Steinberg RM. Simultaneous occurrence of diabetes mellitus, diabetes insipidus, and optic atrophy in a brother and sister. Am J Dis Child 1977, 131(12):1382-1385.
75. de la Monte SM, Tong M, Cohen AC, Sheedy D, Harper C, Wands JR. Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res 2008, 32(9):1630-1644. 10.1111/j.1530-0277.2008.00731.x, 18616667.
76. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009, 42(8):475-481.
77. Giovannone B, Tsiaras WG, de la Monte S, Klysik J, Lautier C, Karashchuk G, Goldwurm S, Smith RJ. GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. Hum Mol Genet 2009, 18(23):4629-4639. 10.1093/hmg/ddp430, 19744960.
78. Busiguina S, Fernandez AM, Barrios V, Clark R, Tolbert DL, Berciano J, Torres-Aleman I. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis 2000, 7(6 Pt B):657-665. 10.1006/nbdi.2000.0311, 11114263.
79. Cohen AC, Tong M, Wands JR, de la Monte SM. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res 2007, 31(9):1558-1573. 10.1111/j.1530-0277.2007.00450.x, 17645580.
80. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 2005, 7(1):45-61.
81. de la Monte SM, Wands JR. Alzheimer's Disease is Type 3 Diabetes: Evidence Reviewed. J Diabetes Science Tech 2008, 2(6):1101-1113.
82. Cole G, Neal JW, Singhrao SK, Jasani B, Newman GR. The distribution of amyloid plaques in the cerebellum and brain stem in Down's syndrome and Alzheimer's disease: a light microscopical analysis. Acta Neuropathol 1993, 85(5):542-552. 10.1007/BF00230495, 8493862.
83. Tong M, de la Monte SM. Mechanisms of ceramide-mediated neurodegeneration. J Alzheimers Dis 2009, 16(4):705-714.
84. Hietanen E, Bartsch H, Ahotupa M, Bereziat JC, Bussacchini-Griot V, Cabral JR, Camus AM, Laitinen M, Wild H. Mechanisms of fat-related modulation of N-nitrosodiethylamine-induced tumors in rats: organ distribution, blood lipids, enzymes and pro-oxidant state. Carcinogenesis 1991, 12(4):591-600. 10.1093/carcin/12.4.591, 1672840.
85. Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans 2004, 32(Pt 1):144-146. 10.1042/BST0320144, 14748735.
86. Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH, Futerman AH. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 2008, 283(9):5677-5684. 10.1074/jbc.M707386200, 18165233.
87. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 2008, 283(20):13538-13548. 10.1074/jbc.M709950200, 2376236, 18359942.
88. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006, 45(1):42-72. 10.1016/j.plipres.2005.11.002, 16445986.
89. Adibhatla RM, Hatcher JF. Altered Lipid Metabolism in Brain Injury and Disorders. Subcell Biochem 2008, 48. nihpa41041.
90. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?. Neurochem Res 2007, 32(4-5):845-856. 10.1007/s11064-007-9297-x, 17342407.
91. Nakane M, Kubota M, Nakagomi T, Tamura A, Hisaki H, Shimasaki H, Ueta N. Lethal forebrain ischemia stimulates sphingomyelin hydrolysis and ceramide generation in the gerbil hippocampus. Neurosci Lett 2000, 296(2-3):89-92. 10.1016/S0304-3940(00)01655-4, 11108988.
92. Weiland D, Mondon CE, Reaven GM. Evidence for multiple causality in the development of diabetic hypertriglyceridaemia. Diabetologia 1980, 18(4):335-340. 10.1007/BF00251016, 6998805.
93. Lijinsky W, Reuber MD, Riggs CW. Dose response studies of carcinogenesis in rats by nitrosodiethylamine. Cancer Res 1981, 41(12 Pt 1):4997-5003.
94. Lijinsky W, Saavedra JE, Reuber MD. Induction of carcinogenesis in Fischer rats by methylalkylnitrosamines. Cancer Res 1981, 41(4):1288-1292.
95. Bansal AK, Bansal M, Soni G, Bhatnagar D. Protective role of Vitamin E pre-treatment on N-nitrosodiethylamine induced oxidative stress in rat liver. Chem Biol Interact 2005, 156(2-3):101-111. 10.1016/j.cbi.2005.08.001, 16144695.
96. Clapp NK, Craig AW, Toya RE. Diethylnitrosamine oncogenesis in RF mice as influenced by variations in cumulative dose. Int J Cancer 1970, 5(1):119-123. 10.1002/ijc.2910050116, 5414737.
97. Butler SM, Ashford JW, Snowdon DA. Age, education, and changes in the Mini-Mental State Exam scores of older women: findings from the Nun Study. J Am Geriatr Soc 1996, 44(6):675-681.
98. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 1996, 275(7):528-532. 10.1001/jama.275.7.528, 8606473.
99. Iizuka S, Suzuki W, Tabuchi M, Nagata M, Imamura S, Kobayashi Y, Kanitani M, Yanagisawa T, Kase Y, Takeda S, Aburada M, Takahashi KW. Diabetic complications in a new animal model (TSOD mouse) of spontaneous NIDDM with obesity. Exp Anim 2005, 54(1):71-83. 10.1538/expanim.54.71, 15725683.
100. Figueroa CD, Taberner PV. Pancreatic islet hypertrophy in spontaneous maturity onset obese-diabetic CBA/Ca mice. Int J Biochem 1994, 26(10-11):1299-1303. 10.1016/0020-711X(94)90099-X, 7851633.
101. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281(15):1401-1406. 10.1001/jama.281.15.1401, 10217056.
102. Dunnett SB, Fibiger HC. Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia. Prog Brain Res 1993, 98:413-420. full_text, 8248529.
103. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, Lobsien D, Barthel H, Brust P, Gertz HJ, Sabri O, Schwarz J. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009, 66(8):866-877. 10.1001/archgenpsychiatry.2009.106, 19652126.
104. Tong M, Dong M, de la Monte SM. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis 2009, 16(3):585-599.
105. Chhabra SK, Souliotis VL, Kyrtopoulos SA, Anderson LM. Nitrosamines, alcohol, and gastrointestinal tract cancer: recent epidemiology and experimentation. In Vivo 1996, 10(3):265-284.
106. Hashimoto K, Takasaki W, Sato I, Tsuda S. DNA damage measured by comet assay and 8-OH-dG formation related to blood chemical analyses in aged rats. J Toxicol Sci 2007, 32(3):249-259. 10.2131/jts.32.249, 17785942.
107. Myers SR, Ali MY. Haemoglobin adducts as biomarkers of exposure to tobacco-related nitrosamines. Biomarkers 2008, 13(2):145-159. 10.1080/13547500701470561, 18270868.
108. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev 2007, 65(6 Pt 2):S39-46. 10.1111/j.1753-4887.2007.tb00327.x, 17605313.
109. Kraegen EW, Cooney GJ. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008, 19(3):235-241. 10.1097/01.mol.0000319118.44995.9a, 18460913.
110. Wang G, Silva J, Dasgupta S, Bieberich E. Long-chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes. Glia 2008, 56(4):449-456. 10.1002/glia.20626, 18205190.
111. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101(7):2070-2075. 10.1073/pnas.0305799101, 357053, 14970312.
112. Han X, D MH, McKeel DW, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002, 82(4):809-818. 10.1046/j.1471-4159.2002.00997.x, 12358786.
113. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev 1997, 23(1-2):47-61. 10.1016/S0165-0173(96)00014-8, 9063586.
114. Gottfries CG, Karlsson I, Svennerholm L. Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr 1996, 8(3):365-372. 10.1017/S1041610296002736, 9116173.
115. Pylypiw HM, Zubroff JR, Magee PN, Harrington GW. The metabolism of N-nitrosomethylaniline. J Cancer Res Clin Oncol 1984, 108(1):66-70. 10.1007/BF00390975, 6746719.
116. Singer GM, Taylor HW, Lijinsky W. Liposolubility as an aspect of nitrosamine carcinogenicity: quantitative correlations and qualitative observations. Chem Biol Interact 1977, 19(2):133-142. 10.1016/0009-2797(77)90026-6, 589698.
117. Hinuma K, Matsuda J, Tanida N, Hori S, Tamura K, Ohno T, Kano M, Shimoyama T. N-nitrosamines in the stomach with special reference to in vitro formation, and kinetics after intragastric or intravenous administration in rats. Gastroenterol Jpn 1990, 25(4):417-424.